Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
December 16, 2025

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over as of February 2025

MARA Rating Company December 16, 2025

Faricimab / vabysmo for treating diabetic macular oedema as of June 2022

MARA Rating Company December 16, 2025

Faricimab / vabysmo for treating wet age-related macular degeneration as of June 2022

MARA Rating Company December 16, 2025

Vabysmo / faricimab for treating visual impairment caused by macular oedema after retinal vein occlusion as of September 2024

MARA Rating Company December 16, 2025

Fedratinib / inrebic for treating disease-related splenomegaly or symptoms in myelofibrosis as of November 2024

MARA Rating Company December 16, 2025

Fintepla / fenfluramine for treating seizures associated with Dravet syndrome as of July 2022

MARA Rating Company December 16, 2025

Fintepla / fenfluramine for treating seizures associated with Lennox-Gastaut syndrome in people 2 years and over as of March 2025

MARA Rating Company December 16, 2025

Filgotinib for treating moderate to severe rheumatoid arthritis as of February 2021

MARA Rating Company December 16, 2025

Filgotinib for treating moderately to severely active ulcerative colitis as of June 2022

MARA Rating Company December 16, 2025

Finerenone / kerendia for treating chronic kidney disease in type 2 diabetes as of March 2023

MARA Rating Company December 16, 2025